Half dose human albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with acute decompensation or acute-on-chronic liver failure undergoing paracentesis less than 5 liters: a randomized controlled trial
- Conditions
- paracentesis-induced circulatory dysfunction acute decompensation or acute-on-chronic liver failureDecompensated cirrhosis, acute-on-chronic liver failure, portal hypertension, acute kidney injury, ascites
- Registration Number
- TCTR20231120001
- Lead Sponsor
- Faculty of Medicine, Prince of Songkla University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
1. Age 18-80
2. Chronic hepatitis disease with acute decompensation or acute-on-chronic liver failure
3. Grade 3 ascites with abdominal distension or respiratory discomfort
4. Ascites release less than 5 liters
1. Disseminated intravascular coagulation
2. Hepatocellular carcinoma, BCLC-D before this treatment
3. Active pulmonary edema or active congestive heart failure on the date of enrollment
4. Serum creatinine > 1.5 mg/dL on the date of enrollment or chronic kidney disease (renal replacement therapy)
5. Gastrointestinal bleeding that cannot be stopped
6. Hemodynamic instability on the date of enrollment (defined as a mean arterial pressure [MAP] of <65 mmHg or escalating doses of vasopressor/inotropic agents required to maintain a MAP value of >65 mmHg within 24 hours)
7. Pregnant
8. The patients has a history of allergy to albumin
9. The patients does not wish to participate in the research project
10. Patients whose life expectancy is through to be less than 2 weeks by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compare patient that has PCCD condition and AKI or hyponatremia between patient that recieved albumin and placebo Beginning of the study and day6 Lab automachine
- Secondary Outcome Measures
Name Time Method survival in hospital or survival in 28 days between patient that recieved albumin and placebo Day before discharge from hospital and day28 Questionaire